human serum, one of which was enriched with human lipoproteins. These serum pools were developed by the National Institute of Public Health and Environmental Hygiene (RIVM), Bilthoven, the Netherlands, to serve as calibrators for cholesterol assays.?
The blood was obtained from volunteer donors, and was tested and found to be negative for HTLV3 antibodies and for HbSAg; nevertheless, all such reference materials should be regarded as potentially hazardous.
The pools were dispensed in 2·0 mL volume with a filling precision of below 0·2'Yu (= I cv) checked by weighing of 2·5% of all vials. The cholesterol concentrations were measured in our reference laboratory in Rotterdam with the manual Abell-Kendall reference method which is identical with the same procedure used by the CDC Lipid Standardization Laboratory. The method is checked regularly in the CDGNHBLI Lipid Standardization Program. Thus, 20 vials from each pool were taken at random from the production line and assayed in duplicate. The analytical precision (cv=0'5%) and accuracy (bias below 1,0%), as well as the 'Certified Reference Method Value' and the 95% uncertainty interval (=tslVn), are mentioned on the package insert. The present batches have concentrations around 4 and 8 mrnol/L. The materials serve as calibrators in the above mentioned standardisation programme in this country; they are available in boxes of six vials from the RIVM at a nominal charge. In vivo and in vitro findings suggest that this hypokalaemia is mediated by~2-adrenoceptor stimulation." Hence, it is relevant that non-selectivẽ -blockade (i.e.~, +~2) prevents the hypokalaemia of AMI 2 and that one of the hypokalaemic AMI patients reported by Rodger et al.' was taking rnetoprolol, a~,-selective blocker.
It would also be of interest to know if any of the AMI patients who did not develop hypokalaemia were on non-selective (i.e.~1~2)~-blockers. Like Mikhailidis and his colleagues, we are interested in the effects of~-blockers on plasma potassium in acute myocardial infarction, and we are grateful for the opportunity to reply to their letter. Five of our patients were on~-blockers and only one was hypokalaemic on admission. Of the four patients who were normokalacmic, two were on non-selective agen,ts and two were on cardioselective agents. Clearly, no conclusions can be drawn from this small study about the relative effects of the two classes of~ blockers. However. we have since examined plasma potassium levels on admission in a much larger number of patients. Our findings have yet to be submitted for publication, but we wish to report here that we have shown that~-blockers can maintain plasma potassium levels in acute myocardial infarction, and that non-selective agents are more effective than cardiosclective agents in this regard. J C RODGER, E SIMPSON Monklands District General Hospital, Airdrie, Lanarkshire M L6 OIS The use of heat-treated plasma for biochemical analysis We read the paper by Collinson, Stein and Light' on the effect of heat treatment of plasma with considerable interest but were surprised that their findings and conclusions differed from our previously reported findings, and those of others, in several important ways. In particular, they recommend that the analytes bicarbonate, chloride and creatinine should not be measured on heated samples but suggest that yglutamyl transferase is suitable for measurement.
We 2 found no clinically significant changes in the first three analytes (we do not consider a statistically significant 2·3% fall in bicarbonate to be clinically significant). Lai et al. ' found no clinically significant changes for creatinine or chloride but did find a 15% fall in bicarbonate. Gow and Fallon' have also reported no 'practical differences' for chloride and creatinine. Also, Houssein, Wilcox and Barron" found no significant changes in the three analytes when measured by Technicon methods.
With regard to y-glutamyl transferase, we reported a clinically very signficant 42% fall on heat treatment, Lai dismiss chloride because they found that values before and after heating were poorly correlated. We would suggest that this poor correlation may not reflect real differences but may just reflect the narrow range over which measurements were made (90-116 mmoUL), a range so narrow that a CV of 1·5% may be expected to produce sufficiently large changes to yield a relatively poor correlation.
Another possible explanation could be a fundamental difference in study design; in our study, and that of Lai et al., all analyses were done on the same batch. Collinson and his colleagues re-analysed the same samples after treatment up to 24 h later. It could therefore be that some of their observed differences are attributable to between assay variation.
In conclusion, we would recommend, contrary to the advice of Collinson et al., that chloride and creatinine can be measured in heat treated samples but that y-glutamyl transferase should not. Clin Chern 1985; 31/12: 2028-30 .
We have read with interest the report by Collinson, Stein and Light, I having carried out similar investigations on 20 heat-treated plasma samples in our own laboratory. We agree that values for albumin, bilirubin, calcium, glucose, phosphate, potassium, sodium, total protein, urate and urea are essentially unchanged or show changes which are not clinically significant. However, our findings for chloride, total carbon dioxide and creatinine differ. Chloride values were not significantly altered and correlation was reasonable (r = 0·96). We measured total carbon dioxide instead of bicarbonate and found no significant difference. We agree that heated samples are unsatisfactory for creatinine. Correlation was good (r = 0·99) but there was an unsatisfactory mean negative bias of 33 umol/L, Sodium, potassium, chloride, total carbon dioxide, glucose urea and creatinine were measured using an I.L.508 analyser [Instrumentation Laboratory (UK) Ltd, Warrington, Cheshire, UK]. Other constituents were measured using a Hitachi 705 analyser [Boehringer Corporation (London) Ltd, Lewes, East Sussex, UK]. Aspartate transaminase and y-glutamyltransferase were not investigated.
These differences illustrate the need for each laboratory to investigate whether heat-treated plasma is suitable for its own methodologies and instrumentation before using this procedure for handling samples from human T cell lymphotropic virus III (HTLV-III) infected patients. 
